{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:36:19Z","timestamp":1758818179382,"version":"3.35.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1002\/jps.21510","type":"journal-article","created":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T19:35:15Z","timestamp":1218051315000},"page":"1532-1544","source":"Crossref","is-referenced-by-count":2,"title":["Physiological Models Are Good Tools to Predict Rat Bioavailability of EF5154 Prodrugs from In Vitro Intestinal Parameters"],"prefix":"10.1016","volume":"98","author":[{"given":"Masahiro","family":"Nomoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tatebayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.21510_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/01.CIR.91.2.403","article-title":"SC-54684A: An orally active inhibitor of platelet aggregation","volume":"91","author":"Nicholson","year":"1995","journal-title":"Circulation"},{"key":"10.1002\/jps.21510_bb0010","first-page":"978","article-title":"In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: An approach for the selection of a prodrug candidate","volume":"25","author":"Prueksaritanont","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.21510_bb0015","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.CIR.96.4.1130","article-title":"Profound and sustained inhibition of platelet aggregation by Fra-dafiban, a nonpeptide platelet glycoprotein IIb\/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men","volume":"96","author":"Muller","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/jps.21510_bb0020","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00019501-199610000-00010","article-title":"Novel nonpeptide antiplatelet glycoprotein IIb\/IIIa receptor antagonist, DMP754: Receptor binding affinity and specificity","volume":"7","author":"Mousa","year":"1996","journal-title":"Coron Artery Dis"},{"key":"10.1002\/jps.21510_bb0025","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1023\/A:1015044318650","article-title":"Prodrug approach for alphaIIbbeta3-peptidomimetic antagonists to enhance their transport in monolayers of a human intestinal cell line (Caco-2): Comparison of in vitro and in vivo data","volume":"16","author":"Kamm","year":"1999","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2125.1999.00931.x","article-title":"Pharmacokinetics and pharmacodynamics of Ro44-3888after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers","volume":"47","author":"Wittke","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jps.21510_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0049-3848(99)00175-9","article-title":"Antiplatelet and antithrombotic effects of orbofi- ban, a new orally active GPIIb\/IIIa antagonist, in guinea pigs","volume":"97","author":"Ogawa","year":"2000","journal-title":"Thromb Res"},{"key":"10.1002\/jps.21510_bb0040","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0022-3565(24)39109-8","article-title":"A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: Active efflux transport as a cause of poor bioavailability of the active drug","volume":"294","author":"Okudaira","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.21510_bb0045","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/jps.21510_bb0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1016086930019","article-title":"Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption","volume":"13","author":"Ribadeneira","year":"1996","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0055","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1023\/A:1020444330011","article-title":"Rate-limited steps of human oral absorption and QSAR studies","volume":"19","author":"Zhao","year":"2002","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1093-3263(02)00163-8","article-title":"Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability","volume":"21","author":"Winiwarter","year":"2003","journal-title":"J Mol Graph Model"},{"key":"10.1002\/jps.21510_bb0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0378-5173(03)00343-0","article-title":"An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs","volume":"263","author":"He","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21510_bb0070","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.48.7.2604-2609.2004","article-title":"Absorption of ester prodrugs in Caco-2 and rat intestine models","volume":"48","author":"He","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21510_bb0075","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1211\/jpp.57.12.0004","article-title":"Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582","volume":"57","author":"Fagerholm","year":"2005","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.21510_bb0080","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0016-5085(89)80072-1","article-title":"Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability","volume":"96","author":"Hidalgo","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1002\/jps.21510_bb0085","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejphar.2007.07.004","article-title":"ME3738 protects against litho-cholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output","volume":"574","author":"Nomoto","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/jps.21510_bb0090","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1021\/js970465w","article-title":"In vitro evaluation of acyloxyalkyl esters as dermal prodrugs of ketoprofen and naproxen","volume":"87","author":"Rautio","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21510_bb0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1018999130076","article-title":"Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: Theoretical development and applications","volume":"10","author":"Sinko","year":"1993","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0169-409X(96)00009-9","article-title":"Transport approaches to the biopharmaceutical design of oral drug delivery systems: Prediction of intestinal absorption","volume":"19","author":"Yu","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21510_bb0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1023\/A:1012103700981","article-title":"Analysis of drug permeation across Caco-2 monolayer: Implication for predicting in vivo drug absorption","volume":"14","author":"Yamashita","year":"1997","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0304-4165(88)90032-3","article-title":"Sub-cellular localization of non-specific carboxylesterases, acylcarnitine hydrolase, monoacylglycerol lipase and palmitoyl-CoA hydrolase in rat liver","volume":"964","author":"Mentlein","year":"1988","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/jps.21510_bb0115","doi-asserted-by":"crossref","first-page":"14769","DOI":"10.1074\/jbc.272.23.14769","article-title":"Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin","volume":"272","author":"Pindel","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1002\/jps.21510_bb0120","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1124\/dmd.106.009381","article-title":"Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine","volume":"34","author":"Imai","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.21510_bb0125","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/dmd.30.5.488","article-title":"Current progress on esterases: From molecular structure to function","volume":"30","author":"Satoh","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.21510_bb0130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1023\/A:1016207525186","article-title":"Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: Relationship to absorption in humans","volume":"12","author":"Stewart","year":"1995","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0135","first-page":"276","article-title":"Pharmacokinetics of prulifloxacin. 1st communication: Absorption, distribution and excretion in rats, dogs and monkeys after a single administration","volume":"47","author":"Okuyama","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/jps.21510_bb0140","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/ci0255782","article-title":"Cheminformatics analysis of organic substituents: Identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups","volume":"43","author":"Ertl","year":"2003","journal-title":"J Chem Inf Comput Sci"},{"key":"10.1002\/jps.21510_bb0145","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/jm970530e","article-title":"Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes","volume":"41","author":"Kansy","year":"1998","journal-title":"J Med Chem"},{"key":"10.1002\/jps.21510_bb0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/1568026013395010","article-title":"Assessing the absorption of new pharmaceuticals","volume":"1","author":"Hidalgo","year":"2001","journal-title":"Curr Top Med Chem"},{"key":"10.1002\/jps.21510_bb0155","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1023\/A:1015892621261","article-title":"Predicting fraction dose absorbed in humans using a macroscopic mass balance approach","volume":"8","author":"Sinko","year":"1991","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0160","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1023\/A:1015885823793","article-title":"Structural specificity of mucosal-cell transport and metabolism of peptide drugs: Implication for oral peptide drug delivery","volume":"9","author":"Bai","year":"1992","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0165","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11095-005-2487-9","article-title":"Lack of improvement of oral absorption of ME3277 by prodrug formation is ascribed to the intestinal efflux mediated by breast cancer resistant protein (BCRP\/ABCG2)","volume":"22","author":"Kondo","year":"2005","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21510_bb0170","first-page":"717","article-title":"Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb\/IIIa receptor antagonist, in rat small intestine","volume":"295","author":"Okudaira","year":"2000","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916329409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916329409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T10:32:23Z","timestamp":1738319543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916329409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0022354916329409"],"URL":"https:\/\/doi.org\/10.1002\/jps.21510","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}